Phenylcyanoguanidines as inhibitors of glucose-induced insulin secretion from beta cells.
3,5-Disubstituted-phenylcyanoguanidines have been identified as activators of SUR1/Kir6.2 potassium channels and as potent inhibitors of insulin release from pancreatic beta cells in vitro.
Tagmose
T M
TM
Discovery and Development, Novo Nordisk A/S, Novo Nordisk Park, DK-2760, Måløv, Denmark.
Mogensen
J P
JP
Agerholm
P C
PC
Arkhammar
P O
PO
Wahl
P
P
Worsaae
A
A
Hansen
J B
JB
D002460:Cell Line; D005947:Glucose / Q000494:pharmacology*; D006146:Guanidines / Q000494:pharmacology*; D006801:Humans; D066298:In Vitro Techniques; D007328:Insulin / Q000378:metabolism*; D007329:Insulin Antagonists / Q000494:pharmacology*; D000078790:Insulin Secretion; D007515:Islets of Langerhans / Q000187:drug effects* / Q000378:metabolism
D006146:Guanidines; D007328:Insulin; D007329:Insulin Antagonists; D005947:Glucose